SciSparc Ltd. (NASDAQ:SPRC) saw its share price leap about 200% on Thursday after its subsidiary, NeuroThera Labs Inc. (TSXV:NTLX), obtained conditional regulatory approval from the TSX Venture Exchange to proceed with the acquisition of an approximate 54% interest in CliniQuantum Ltd.
The transaction was originally disclosed in March 2026. Under the terms of the share purchase agreement, NeuroThera will receive 56,375 ordinary shares in CliniQuantum, which constitute roughly 54% of CliniQuantum's issued and outstanding share capital. In return, NeuroThera will issue 56,600,000 of its own common shares to the selling shareholders. The issued NeuroThera shares are valued at about $9.5 million based on the 20-day volume-weighted average trading price used in the agreement.
CliniQuantum is a privately held Israeli technology company that is building a platform that applies quantum simulation and quantum Monte Carlo techniques to the analysis of clinical trial data. Its primary asset is an exclusive, worldwide license agreement with Quantum X Labs Ltd. for a United States provisional patent application titled "Generating Quantum Markov Chain Monte Carlo Sampling Points for Continuous Distribution Functions."
Parties to the transaction adjusted their arrangement on April 30, 2026 through an amendment to the original share purchase agreement. That amendment established a floor price of $0.05 per common share for any shares issued as part of earn-out payments, aligning the mechanism with TSX policies. The amendment also extended the completion deadline from April 30, 2026 to June 1, 2026 to provide extra time to meet outstanding closing conditions.
Among the outstanding closing items cited is obtaining an Israeli tax ruling and securing final acceptance from the TSX Venture Exchange. To secure the transaction mechanics, the selling shareholders will place the 56,600,000 consideration shares into escrow under a Form 5D Escrow Agreement.
The conditional approval from the TSX Venture Exchange signals a key procedural advancement for NeuroThera’s planned acquisition, but final completion remains contingent on satisfying the remaining conditions and regulatory steps outlined in the agreement and its amendment.
Summary of transaction mechanics
- NeuroThera to acquire 56,375 ordinary shares of CliniQuantum, representing about 54% ownership.
- Consideration to sellers: 56,600,000 NeuroThera common shares, valued at approximately $9.5 million using the 20-day VWAP.
- Amendment sets a $0.05 per share floor for earn-out share issuances and extends the closing deadline to June 1, 2026.
- Selling shareholders will deposit the consideration shares into escrow under a Form 5D Escrow Agreement.
The approval and related contractual amendments were enough to prompt a marked market reaction in SciSparc’s stock, though the transaction itself still requires completion of remaining conditions, including an Israeli tax ruling and final TSXV acceptance.
Key takeaways
- Corporate control - The deal would give NeuroThera a majority stake in CliniQuantum, transferring immediate strategic control if completed.
- Technology and health data analysis - CliniQuantum’s licensed quantum simulation and quantum Monte Carlo methods are positioned to be applied to clinical trial data analytics.
- Capital markets - The share-based consideration and escrow arrangement reflect financing and regulatory mechanics that impact equity holders of NeuroThera and its parent SciSparc.
Risks and uncertainties
- Regulatory and tax clearances - Completion depends on obtaining an Israeli tax ruling and final TSX Venture Exchange acceptance, conditions that remain outstanding.
- Earn-out mechanics - Shares tied to earn-out payments are subject to a floor price and TSX policy constraints, which could affect future dilution outcomes for NeuroThera shareholders.
- Escrow and closing conditions - The placing of consideration shares into escrow and the extension to June 1, 2026 indicate conditionality; the transaction is not yet finalized.
The conditional approval is a procedural milestone that has so far produced a strong market response for SciSparc, but the ultimate transfer of control and the operational integration of CliniQuantum into NeuroThera will depend on the successful resolution of the remaining conditions documented in the amended share purchase agreement.